| scholarly article | Q13442814 |
| P2093 | author name string | Sergei Tjulandin | |
| Alexey Tryakin | |||
| Dheepak Kanagavel | |||
| Mikhail Fedyanin | |||
| P2860 | cites work | Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1 | Q80179117 |
| A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy | Q80371789 | ||
| Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study | Q80527609 | ||
| A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) | Q80789086 | ||
| Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer | Q82931072 | ||
| Optimal indications for second-line chemotherapy in advanced gastric cancer | Q83194207 | ||
| A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Tria | Q83900980 | ||
| CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702) | Q87139738 | ||
| Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study | Q87412958 | ||
| Chemotherapy for advanced gastric cancer | Q24236634 | ||
| Receptor specificity of the fibroblast growth factor family | Q24320178 | ||
| Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 | ||
| Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer | Q27320322 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Identification of a new fibroblast growth factor receptor, FGFR5 | Q28202842 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. | Q31120096 | ||
| Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). | Q33228157 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer | Q33366124 | ||
| Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin | Q33373223 | ||
| Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). | Q33378671 | ||
| Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer | Q33381350 | ||
| Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens | Q33386661 | ||
| Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Q33389519 | ||
| Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer | Q33391768 | ||
| Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study | Q33410627 | ||
| Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study | Q33413448 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study | Q33419166 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Phase II study of paclitaxel in pretreated advanced gastric cancer | Q33502836 | ||
| Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. | Q33710574 | ||
| Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer | Q33733751 | ||
| Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens | Q46175387 | ||
| Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer | Q46388902 | ||
| A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial | Q46564784 | ||
| Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study | Q46569543 | ||
| The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation | Q46580742 | ||
| Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma | Q46634764 | ||
| Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis | Q46796721 | ||
| The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. | Q46817815 | ||
| ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy | Q46888766 | ||
| Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment | Q46925408 | ||
| Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer | Q46957212 | ||
| Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. | Q47977393 | ||
| The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor | Q48017929 | ||
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
| Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. | Q50962533 | ||
| Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. | Q50975757 | ||
| A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. | Q52014045 | ||
| Prognostic score of gastric cancer determined by cDNA microarray. | Q52028601 | ||
| Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 | ||
| Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. | Q53574197 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. | Q54571851 | ||
| The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression | Q54649699 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study | Q57192409 | ||
| Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer | Q59573909 | ||
| Gastric cancer | Q71681994 | ||
| Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study | Q77364411 | ||
| The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas | Q77386062 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research | Q34581504 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis | Q34655369 | ||
| Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv | Q34665199 | ||
| Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. | Q35051856 | ||
| TP53 and gastric carcinoma: a review | Q35078746 | ||
| Chemotherapy in gastric cancer: a review and updated meta-analysis | Q35108798 | ||
| Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies | Q35288940 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Review of second-line chemotherapy for advanced gastric adenocarcinoma | Q36097966 | ||
| Tissue expression of PD-L1 mediates peripheral T cell tolerance. | Q36228541 | ||
| PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma | Q36506366 | ||
| MET expression and amplification in patients with localized gastric cancer | Q36949256 | ||
| Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? | Q36964966 | ||
| Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients | Q37050510 | ||
| Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer | Q37222473 | ||
| Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study | Q37425848 | ||
| Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). | Q37491365 | ||
| Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer | Q37709811 | ||
| Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. | Q39172509 | ||
| FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. | Q39181047 | ||
| A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma | Q39252506 | ||
| Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy | Q40538283 | ||
| Preoperative chemotherapy of locally advanced gastric cancer. | Q40762990 | ||
| Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer | Q41475235 | ||
| Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial | Q41503961 | ||
| Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). | Q42227431 | ||
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
| Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | Q42775676 | ||
| A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy | Q43164688 | ||
| Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer | Q43268388 | ||
| Gene expression profile predicts patient survival of gastric cancer after surgical resection | Q44081404 | ||
| Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). | Q44687159 | ||
| Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma | Q44695858 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy | Q44923328 | ||
| Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen | Q45185901 | ||
| Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer | Q45345168 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 11621-35 | |
| P577 | publication date | 2015-11-07 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Second-line treatment of metastatic gastric cancer: Current options and future directions | |
| P478 | volume | 21 |
| Q39028389 | Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells. |
| Q55313144 | Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer. |
| Q64069303 | Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data |
| Q33580666 | KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer |
| Q37697309 | MAGI1 inhibits migration and invasion via blocking MAPK/ERK signaling pathway in gastric cancer |
| Q41682632 | MicroRNA-200c is involved in proliferation of gastric cancer by directly repressing p27Kip1. |
| Q26738548 | New advances in targeted gastric cancer treatment |
| Q49350269 | Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices |
| Q91851580 | Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial |
| Q36784611 | Second Primary Malignancies in Adults with Gastric Cancer - A US Population-Based Study |
| Q55176833 | TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study. |
Search more.